Τα απαγορευμένα σποτάκια και η ανακοίνωση του Φαρμακευτικού Συλλόγου Αττικής

AΘΗΝΑ   6  ΜΑΪΟΥ   2014        

                                                                  ΠΡΟΣ

                       

-      Μ.Μ.Ε.

-      ΟΛΑ ΤΑ ΚΟΜΜΑΤΑ

ΔΕΛΤΙΟ ΤΥΠΟΥ

«ΦΙΜΩΣΗ ΤΗΣ ΔΗΜΟΚΡΑΤΙΑΣ»

Η κυβέρνηση προχώρησε σήμερα, σε μία πρωτοφανή πράξη φίμωσης του Δημοκρατικού λόγου, και της ελεύθερης έκφρασης πολιτικών φορέων, συνδικαλιστικών οργανώσεων επιστημονικών κλάδων κ.λ.π.

Απαγορεύει με Υπουργική Απόφαση την μετάδοση οποιουδήποτε μηνύματος μπορεί να χαρακτηριστεί από την κυβέρνηση ως πολιτικό και που προφανώς «θα την βλάψει» ενόψει των επερχόμενων εκλογών.

Αυτή η πρωτοφανής λογοκρισία δεν έχει προηγούμενο σε μία ευνομούμενη Δημοκρατία.

Ο ΦΣΑ καλεί όλα τα κόμματα να πάρουν θέση. Δηλώνει προς κάθε κατεύθυνση ότι με αυτές τις ενέργειες οι φαρμακοποιοί πεισμώνουν ακόμη περισσότερο και θα δυναμώσουν τους αγώνες τους.  Να είναι σίγουροι οι εμπνευστές – λογοκριτές ότι οι φαρμακοποιοί θα καταδικάσουν και με την ψήφο τους, αυτούς που τα τελευταία χρόνια έχουν οδηγήσει ολόκληρη την κοινωνία σε ανθρωπιστική κρίση.

ΓΙΑ ΤΟΝ Φ.Σ.Α.

Ο   ΠΡΟΕΔΡΟΣ                                                 Ο ΓΡΑΜΜΑΤΕΑΣ

ΚΩΝΣΤΑΝΤΙΝΟΣ  ΛΟΥΡΑΝΤΟΣ                      ΗΛΙΑΣ  ΓΙΑΝΝΟΓΛΟΥ


Δείτε εδώ τα απαγορευμένα σποτάκια

https://www.youtube.com/watch?v=jQ07s3E1WFE&feature=youtu.be

https://www.youtube.com/watch?v=7Q_5iuS27DE&feature=youtu.be

 

Three days left to get registered at the early bird rate to attend the “Pharmaceutical Marketing for Non – Marketers” seminar.

30 - 31 of May - Metropolitan Hotel, Athens

Early Bird Registrations until, Friday 9th May. 


Click here to download the seminar brochure: 

https://www.dropbox.com/s/ua7bfnkh4c9bmg3/Pharma%20Marketing%20for%20Non%20Marketers.pdf
  

Novartis and GSK’s multi-billion dollar swaps to transform both companies

Novartis has unveiled a dazzling multi-billion dollar business deal which sees it divest its vaccines and animal health divisions, build its oncology portfolio, and create a new joint venture market leader in OTC medicines. The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 billion dependent on milestones.

The deal will not only transform Novartis, but GSK as well, with both companies clearly focusing on strategies to make them true market leaders in their chosen areas. The underlying thinking for both firms is to exit therapy areas where they are an 'also ran' and create critical mass in key areas.

Three days left to get registered at the early bird rate to attend the “Pharmaceutical Marketing for Non – Marketers” seminar.

30 - 31 of May - Metropolitan Hotel, Athens

Early Bird Registrations until, Friday 9th May.

Click here to download the seminar brochure: 

https://www.dropbox.com/s/ua7bfnkh4c9bmg3/Pharma%20Marketing%20for%20Non%20Marketers.pdf

The deal also see Novartis divest its animal health division to Lilly for around $5.4 billion.

Creating market leading franchises

For Novartis, oncology is a key strategic area, but it is still short of dominating the field.

Bayer aims to crush consumer health rivals with $14B Merck unit buyout

Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co., Inc., Whitehouse Station, NJ, USA, for a purchase price of USD 14.2 billion (EUR 10.4 billion). "This acquisition marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business," explained Bayer CEO Dr. Marijn Dekkers. "At the same time we are leveraging our capabilities in the cardiovascular therapeutic area." In a related transaction, Bayer has entered into a global co-development and co-commercialization agreement with Merck & Co., Inc. in the field of soluble guanylate cyclase (sGC) modulators, for which Merck & Co., Inc. will make an up-front payment to Bayer of USD 1 billion, with substantial additional sales milestone payments.

Significant enhancement of Bayer's consumer care business

The acquisition will give Bayer the global number two position in non-prescription (over-the-counter, OTC) products following recently announced consolidations in this highly attractive and growing healthcare industry segment, and will significantly enhance Bayer's business across multiple therapeutic categories and geographies. Merck & Co., Inc.'s consumer care business includes leading brands such as Claritin™, Coppertone™ and Dr. Scholl's™.